NSE
MANGALAM

Mangalam Drugs And Organics Limited

Drug Manufacturers-Specialty & Generic
Healthcare

Prices are adjusted according to historical splits.

Mangalam Drugs And Organics Limited Stock Price

Vitals

Today's Low:
₹104.75
Today's High:
₹109
Open Price:
₹107.55
52W Low:
₹95
52W High:
₹172.65
Prev. Close:
₹107.5
Volume:
16955

Company Statistics

Market Cap.:
₹1.68 billion
Book Value:
95.98
Revenue TTM:
₹3.48 billion
Operating Margin TTM:
-0.17%
Gross Profit TTM:
₹1.22 billion
Profit Margin:
-3.24%
Return on Assets TTM:
2.64%
Return on Equity TTM:
0.84%

Company Profile

Mangalam Drugs And Organics Limited had its IPO on under the ticker symbol MANGALAM.

The company operates in the Healthcare sector and Drug Manufacturers-Specialty & Generic industry. Mangalam Drugs And Organics Limited has a staff strength of 0 employees.

Stock update

Shares of Mangalam Drugs And Organics Limited opened at ₹107.55 at the start of the last trading session i.e. 2023-09-13.

The stocks traded within a range of ₹104.75 - ₹109, and closed at ₹105.1.

This is a -2.23% slip from the previous day's closing price.

A total volume of 16,955 shares were traded at the close of the day’s session.

In the last one week, shares of Mangalam Drugs And Organics Limited have increased by +0.14%.

Mangalam Drugs And Organics Limited's Key Ratios

Mangalam Drugs And Organics Limited has a market cap of ₹1.68 billion, indicating a price to book ratio of 1.4081 and a price to sales ratio of 0.4963.

In the last 12-months Mangalam Drugs And Organics Limited’s revenue was ₹3.48 billion with a gross profit of ₹1.22 billion and an EBITDA of ₹110.20 million. The EBITDA ratio measures Mangalam Drugs And Organics Limited's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Mangalam Drugs And Organics Limited’s operating margin was -0.17% while its return on assets stood at 2.64% with a return of equity of 0.84%.

In Q2, Mangalam Drugs And Organics Limited’s quarterly earnings growth was a negative -89.4% while revenue growth was a negative 19.2%.

Mangalam Drugs And Organics Limited’s PE and PEG Ratio

Forward PE
0
Trailing PE
0
PEG

Its diluted EPS in the last 12-months stands at ₹-7.15 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Mangalam Drugs And Organics Limited’s profitability.

Mangalam Drugs And Organics Limited stock is trading at a EV to sales ratio of 0.6668 and a EV to EBITDA ratio of 7.494. Its price to sales ratio in the trailing 12-months stood at 0.4963.

Mangalam Drugs And Organics Limited stock pays annual dividends of ₹0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
₹19.90 billion
Total Liabilities
₹7.79 billion
Operating Cash Flow
₹0
Capital Expenditure
₹0
Dividend Payout Ratio
0%

Mangalam Drugs And Organics Limited ended 2024 with ₹19.90 billion in total assets and ₹0 in total liabilities. Its intangible assets were valued at ₹19.90 billion while shareholder equity stood at ₹7.56 billion.

Mangalam Drugs And Organics Limited ended 2024 with ₹0 in deferred long-term liabilities, ₹7.79 billion in other current liabilities, 274973000.00 in common stock, ₹7.29 billion in retained earnings and ₹0 in goodwill. Its cash balance stood at ₹507.84 million and cash and short-term investments were ₹2.36 billion. The company’s total short-term debt was ₹3,206,284,000 while long-term debt stood at ₹2.91 billion.

Mangalam Drugs And Organics Limited’s total current assets stands at ₹6.69 billion while long-term investments were ₹0 and short-term investments were ₹931.80 million. Its net receivables were ₹369.98 million compared to accounts payable of ₹970.73 million and inventory worth ₹2.57 billion.

In 2024, Mangalam Drugs And Organics Limited's operating cash flow was ₹0 while its capital expenditure stood at ₹0.

Comparatively, Mangalam Drugs And Organics Limited paid ₹0 in dividends in 2024.

Other key metrics

Current Trading Price
₹105.1
52-Week High
₹172.65
52-Week Low
₹95
Analyst Target Price

Mangalam Drugs And Organics Limited stock is currently trading at ₹105.1 per share. It touched a 52-week high of ₹172.65 and a 52-week low of ₹172.65. Analysts tracking the stock have a 12-month average target price of .

Its 50-day moving average was ₹106.84 and 200-day moving average was ₹114.6 The short ratio stood at 0 indicating a short percent outstanding of 0%.

Around 5659.7% of the company’s stock are held by insiders while 0% are held by institutions.

Frequently Asked Questions About Mangalam Drugs And Organics Limited

The stock symbol (also called stock or share ticker) of Mangalam Drugs And Organics Limited is MANGALAM

The IPO of Mangalam Drugs And Organics Limited took place on

Similar Industry Stocks (Drug Manufacturers-Specialty & Generic)

Last Price
Chg
Chg%
₹86.13
-4.19
-4.64%
₹37.49
0.59
+1.6%
₹21.29
-0.83
-3.75%
Veritone Inc (VERI)
₹2.73
-0.11
-3.87%
₹10502.8
-32.1
-0.3%
₹4.55
0.11
+2.48%
₹0.79
-0.01
-1.25%
₹106.6
0.99
+0.94%
₹13.78
-0.2
-1.43%
₹0.54
0.07
+14.89%

Most Active

Last Price
Chg
Chg%
Amyris Inc (AMRS)
₹0.14
0.07
+100%
₹0.12
0.04
+45.29%
₹0.96
0.05
+5.4%
₹1.34
-0.35
-20.71%
Humbl Inc (HMBL)
₹0
0
0%

Top Gainers

Last Price
Chg
Chg%
₹0
0
+172200%
₹0
0
+51200%
₹283
280.03
+9428.62%
₹11.2
10.57
+1667.68%
Latch Inc (LTCHW)
₹0.01
-0.03
+1550%

Top Losers

Last Price
Chg
Chg%
₹0.19
-123.15
-99.85%
₹0
-0.11
-99.55%
₹0
-0
-97.96%
₹0
-0.01
-93.94%
₹0.01
-0.06
-92.24%

About

Mangalam Drugs & Organics Limited manufactures and sells active pharmaceutical ingredients (APIs) and intermediates at VAPI in India and internationally. It offers a range of API products, which include Acyclovir, Amodiaquine, Artemether, Artesunate, Atorvastatin Calcium, Atazanavir Sulfate, Bisoprolol Fumarate, Chloroquine Phosphate, and Dolutegravir Sodium; Efavirenz, Emtricitabine, Furosemide, Hydroxychloroquine Sulphate, Lumefantrine, and Nimesulide; Nitrofurantoin Anhydrous and Monohydrate; Primaquine and Piperaquine Phosphate; Pregabalin, Pyrimethamine, Pyronaridine Tetraphosphate, and Sulfadoxine; and Tenofovir Alafenamide Hemifumarate and Disoproxil Fumarate. The company also offers intermediates comprising 2-Dibutylamino-1-(2,7-dichloro-9H-fluorine-4-yl)-ethanol; 4,6-Dichloro-5-methoxy pyrimidine; 4,7 Dichloroquinoline; Ortho phenoxy methane sulfonanilide; and Tenofovir Alafenamide Base and Disoproxil Base. In addition, it offers specialty chemicals, such as Menthol; 2,3-Dihydrophthalazine-1, 4-dione; and 4-cynoethyl-2-methyl phenol. The company was incorporated in 1972 and is based in Mumbai, India.

Address